Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19151672 | 0.86 | ALDH1A1 (0.39) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL3244594 | 0.86 | ALDH1A1 (0.46) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL3250456 | 0.86 | HDAC6 (0.43) | ALDH1A1HDAC4HDAC6HDAC1HDAC3 | |
| SCHEMBL20082302 | 0.85 | HDAC6 (0.42) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL3247527 | 0.85 | HDAC6 (0.42) | ALDH1A1HDAC4HDAC6HDAC1HDAC3 | |
| SCHEMBL3253468 | 0.84 | ALDH1A1 (0.38) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL21230185 | 0.81 | HDAC4 (0.35) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL21230173 | 0.81 | ALDH1A1 (0.39) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL3262869 | 0.81 | HDAC4 (0.50) | ALDH1A1RAB9ANPC1HDAC4HDAC6 | |
| SCHEMBL3241342 | 0.81 | TP53 (0.45) | ALDH1A1HDAC4HDAC6HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-10053467-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-21 | — | — | US | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2012-08-09 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| EP-2182809-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053467-B2 | Therapeutic isoxazole compounds | MAOB, MAOA, XDH | ALDH1A1 254/4885RAB9A 2123/4885NPC1 3017/4885 |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885RAB9A 2123/4885NPC1 3017/4885 |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885RAB9A 2123/4885NPC1 3017/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885RAB9A 2123/4885NPC1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.